Navigation Links
Depolarization-induced suppression of inhibition


Depolarization-induced suppression of inhibition (DSI) is the classical and original electrophysiological example of endocannabinoid function in the central nervous system. Prior to the demonstration that DSI was dependent on the cannabinoid CB1 receptor function, there was no way of producing an in vitro endocannabinoid mediated effect.

DSI is classically produced in a brain slice experiment (i.e. a 300-400 µm slice of brain, with intact axons and synapses) where a single neuron is "depolarized" (the normal −70 mV potential across the neuronal membrane is reduced, usually to −30 to 0 mV) for a period of 1 to 10 seconds. After the depolarization, inhibitory GABA mediated neurotransmission is reduced. This has been demonstrated to be caused by the release of endogenous cannabinoids from the depolarized neuron which diffuses to nearby neurons, and binds and activates CB1 receptors, which act presynaptically to reduce neurotransmitter release.

Contents

History

DSI was discovered in 1992 by two different laboratories (Pitler & Alger, 1992; Vincent et al, 1992), one working with pyramidal cells in the hippocampus and another working with Purkinje cells in the cerebellum.

These groups were studying the responses of large pyramidal projection neurons to GABA, the main inhibitory neurotransmitter in the central nervous system. GABA is typically released by small interneurons in many regions of the brain, where its job is to inhibit the activity of primary neurons, such as the CA1 pyramidal neurons of the hippocampus or the Purkinje cells of the cerebellum. Activation of GABA receptors on these cells, whether they are ionotropic or metabotropic, typically results in the influx of chloride ions into that target cell. This build-up of negative charge from the chloride ions results in the hyperpolarization of the target cell, making it less likely to fire an action potential. Accordingly, any ionic current that hyperpolarizes a cell is called an inhibitory current.

In their experiments with projection neurons in the hippocampus and cerebellum, both groups noticed that a train of action potentials in these cells resulted in a temporary reduction in inhibitory currents caused by GABA-ergic interneurons. Since this reduction of inhibitory currents could be invoked simply by depolarization of the target cell, this phenomenon was termed depolarization-induced suppression of inhibition, or DSI. While initially discovered in CA1 neurons of the hippocampus and Purkinje cells in the cerebellum, DSI is a pretty ubiquitous phenomenon and has been demonstrated in other areas of the brain such as the basal ganglia, the cortex, the amygdala, and the hypothalamus (Katona et al. 2001, Jo et al. 2005, Bodor et al. 2005, Matyas et al. 2006)

DSI mediation by endocannabinoids

DSI was thought to be due to a reduction in pre-synaptic neurotransmitter release for 2 reasons. 1) The magnitudes of spontaneously evoked inhibitory post-synaptic currents (IPSCs), caused by the release of a single pre-synaptic vesicle filled with GABA, remained unchanged and 2) The cellular responses to exogenously applied GABA remained the same. These observations suggested that no changes occurred in the post-synaptic cell to change its responsiveness to GABA during DSI. Somehow, DSI appeared to be mediated by a retrograde synaptic messenger whose synthesis or release was stimulated by the depolarization of the target cell. This messenger then diffused "backwards" to the pre-synaptic cell, where it caused a reduction in neurotransmitter release.

The chemical messengers presumed to be responsible for mediating DSI was discovered by three separate groups in 2001. Wilson & Nicoll (2001) published their work in the prestigious journal, Nature, while the other two groups, Kreitzer & Regehr (2001) and Ohno-Shosaku et al. (2001), published in the same issue of another reputable journal, Neuron. All three demonstrated heavy involvement of the CB1 cannabinoid receptor in DSI, suggesting that the endocannabinoids were the brain's mediators of DSI. They showed that cannabinoid receptor agonists, drugs that mimic the actions of endocannabinoids or THC, could evoke the same reduction in inhibitory currents caused by DSI. They also demonstrated that DSI could be prevented by cannabinoid receptor antagonists, drugs that block the actions of cannabinoid compounds.

Other lines of evidence support the role of the CB1 receptor in DSI. This receptor is distributed very widely throughout the brain, covering all areas where DSI has been observed (Herkenham et al. 1990). The CB1 receptor also appears to be expressed mainly on GABA-ergic pre-synaptic terminals, making it an excellent candidate for mediating DSI (Matyas et al. 2006, Katona et al. 1999). In 2005, other groups began to demonstrate the involvement of the CB1 receptor in DSI in other regions of the brain (Jo et al. 2005, Bodor et al. 2005). Lastly, DSI research was finally applied to mice that had the CB1 receptor genetically "knocked-out". So far, these knock-out mice are not known to exhibit DSI in any regions of the brain, suggesting that the CB1 receptor is the crucial mediator for DSI (Kreitzer & Regehr 2001a, Ohno-Shosaku et al. 2002).

The discovery that DSI is mediated by endocannabinoids finally explained why both the CB1 receptor and the endocannabinoids are both so widely distributed in the brian. DSI is a very common form of short-term plasticity and thus needs to be mediated by a commonly found neurotransmitter. The use of endocannabinoids such as anandamide and 2-arachidonoyl glycerol in this method of signalling is quite logical, since both molecules can be synthesized relatively easily from lipids in the plasma membrane, a fundamental constituent of all cells. DSI is therefore the primary cortical process mediated by the endocannabinoids, and may contribute to many forms of cortical plasticity and synaptic strengthening, such as in long-term potentiation (Carlson et al. 2002).

A note on DSE

While working with the cerebellum, Kreitzer's group also discovered that depolarization of Purkinje cells could also cause a temporary reduction in excitatory input into these cells from both climbing fibres and parallel fibres (Kreitzer et al. 2001b). This phenomenon was termed depolarization-induced suppression of excitation (DSE), and differs from DSI only by the kind of neurotransmitter whose release is reduced. In the case of DSI, the result is a reduction in inhibitory GABA release, while in DSE the effect is a reduction in excitatory glutamate release. DSE was also found to occur in other regions of the brain, however the evidence for the involvement of the endocannabinoid receptor CB1 in this process is not as solid as it is for DSI. Both DSI and DSE have been studied in the CB1 knock-out mice. Some groups show that both DSI and DSE are lacking in these mice, while others have shown that DSE, but not DSI, can still be evoked in the knock-outs (Ohno-Shosaku et al. 2002, Hajos et al. 2001). The endocannabinoids may still mediate DSE too, but by acting at an as-of-yet unknown cannabinoid receptor. Interestingly, some work has shown that anandamide can bind to the vannilloid receptor VR1, known as the capsaicin receptor. This receptor is present in the brain, and anandamide actions at this receptor may potentially contribute to DSE (Cristino et al. 2006, Hajos et al. 2002). However DSE is currently a largely unexplored phenomenon and more research is needed to draw any firm conclusions.

References

  • Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, Freund TF. (2005) Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. Jul 20;25(29):6845-56.
  • Carlson G, Wang Y, Alger BE. (2002) Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci. Aug;5(8):723-4.
  • Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. (2006) Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. Apr 5; In Press.
  • Hajos N, Freund TF. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology. Sep;43(4):503-10.
  • Hajos N, Ledent C, Freund TF. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106(1):1-4.
  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. Mar;87(5):1932-6.
  • Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW. (2005) Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron. Dec 22;48(6):1055-66.
  • Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. Dec 1;21(23):9506-18.
  • Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. Jun 1;19(11):4544-58.
  • Kreitzer AC, Regehr WG. (2001a). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29(3):717-27
  • Kreitzer AC, Regehr WG. (2001b) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci. Oct 15;21(20):RC174.
  • Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience.137(1):337-61.
  • Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. (2002) Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci. May 15;22(10):3864-72.
  • Ohno-Shosaku T, Maejima T, Kano M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29(3):729-38
  • Pitler TA, Alger BE. (1992). Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 12:4122-4132.
  • Vincent P, Armstrong CM, Marty A. (1992) Inhibitory synaptic currents in rat cerebellar Purkinje cells: modulation by postsynaptic depolarization. J. Physiol. (London) 456, p. 453–471.
  • Wilson RI, Nicoll RA. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410(6828):588-92

Further reading

  • Alger BE. (2002). Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68:247-286.
  • Freund TF, Katona I, Piomelli D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066.

'"/>


(Date:4/24/2014)... more than 15 years ago, the PTEN gene has ... the onset and progression of numerous cancers. Consequently, when ... grow unchecked and cancer can develop. , Now a ... Center (BIDMC) helps explain more precisely how PTEN exerts ... can set cells on a cancerous course. The new ...
(Date:4/24/2014)... Benefits often coexist with the negative and stressful outcomes ... later diagnosed with a life-limiting illness, says a recent ... Waterloo. , While the challenges are numerous and life-changing ... who participated in the Waterloo-led research reported positive outcomes ... findings appear in the most recent issue of the ...
(Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
(Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... of the new health reform in China have been ... one of the most important policies ,The National Essential ... solve the high cost of drugs in China through ... drug prices that cover a wide range of diseases ...
... Million Contribution Mark to Support Families Living with Autism and Other ... ... -- Safeway (NYSE:SWY) captures Easter Seals, highest ... for children and adults with autism and other disabilities in 2009 ...
... celebrating their 50th year anniversary this month. Founded in 1959, ... various industries. In the 1970s, Key Instruments began focusing exclusively ... flow meters, and then expanded to include molded flow meters, ... ...
... tattoo to fit horizontal tummy tuck and c-section scars. It is made ... was designed to last 1-3 days. It can be applied and removed ... ... ScarArt, an innovative new company specializing in adhesive products used to conceal ...
... provide affordable and timely transcription services , ... ... Inc., the nation,s leading provider of transcription services to group ... will incorporate M*Modal,s Conversational Documentation Services (CDS) ...
... NuSil Technology announced a definitive agreement to acquire the pharmaceutical ... ... Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil ... silicone compounds for the healthcare and pharmaceutical industries, announced a ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:Key Instruments Celebrates 50 Year Anniversary 2Health News:Key Instruments Celebrates 50 Year Anniversary 3Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 3Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3
Other medicine definitionOther Tags